Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood

Zhang,Qian; Wang,Lili; Luo,Chenghan; Shi,Zanyang; Cheng,Xinru; Zhang,Zhen; Yang,Yi; Zhang,Yi

doi:10.3892/or.2014.3457

Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood

Authors:
- Qian Zhang
- Lili Wang
- Chenghan Luo
- Zanyang Shi
- Xinru Cheng
- Zhen Zhang
- Yi Yang
- Yi Zhang
View Affiliations

Affiliations: Department of Neonatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Newborn Disease Key Laboratory of the Ministry of Health, The Children's Hospital Affiliated to Fudan University, Shanghai 201102, P.R. China
Published online on: September 1, 2014 https://doi.org/10.3892/or.2014.3457
Pages: 2244-2252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cord blood has gradually become an important source for hematopoietic stem cell transplantation (HSCT) in the human, particularly in pediatric patients. Adoptive cellular immunotherapy of patients with hematologic malignancies after umbilical cord blood transplant is crucial. Cytokine‑induced killer (CIK) cells derived from cord blood are a new type of antitumor immune effector cells in tumor prevention and treatment and have increasingly attracted the attention of researchers. On the other hand, it has been suggested that preterm infant cord blood retains an early differentiation phenotype suitable for immunotherapy. Therefore, we determined the phenotypic and functional characterization of CIK cells derived from preterm infant cord blood (PCB-CIK) compared with CIK cells from term infant cord blood (TCB-CIK). Twenty cord blood samples were collected and classified into two groups based on gestational age. Cord blood mononuclear cells (CBMCs) were isolated, cultured and induced to CIK cells in vitro. We used flow cytometry to detect cell surface markers, FlowJo software to analyze the proliferation profile and intracellular staining to test the secretion of cytokines. Finally, we evaluated the antitumor activity of CIK cells against K562 in vitro. Compared with TCB-CIK, PCB-CIK cells demonstrated faster proliferation and higher expression of activated cell surface markers. The secretion of IL-10 was lower in PCB-CIK cells while the expression of perforin and CD107a had no significant difference between the two cell groups. PCB-CIK cells exhibited a high proliferation rate while the cytotoxic activity had no difference between the PCB-CIK and TCB-CIK cells. Hence preterm infant cord blood may be a potential source for immunotherapy.

View Figures

View References

1	Bear AS, Hanley PJ, Bosque DM, et al: Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. 16:1153–1157. 2014. View Article : Google Scholar : PubMed/NCBI
2	Humphries C: Adoptive cell therapy: honing that killer instinct. Nature. 504:S13–S15. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yee C: Adoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res. 19:4550–4552. 2013. View Article : Google Scholar : PubMed/NCBI
4	Restifo NP, Dudley ME and Rosenberg SA: Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 12:269–281. 2012. View Article : Google Scholar : PubMed/NCBI
5	Schmidt-Wolf IG, Negrin RS, Kiem HP, et al: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
6	Pievani A, Borleri G, Pende D, et al: Dual-functional capability of CD3⁺CD56⁺ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 118:3301–3310. 2011.PubMed/NCBI
7	Liu L, Zhang W, Qi X, et al: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
8	Gammaitoni L, Giraudo L, Leuci V, et al: Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res. 19:4347–4358. 2013. View Article : Google Scholar
9	Laport GG, Sheehan K, Baker J, et al: Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 17:1679–1687. 2011. View Article : Google Scholar
10	Ma YJ, He M, Han JA, et al: A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. Scand J Immunol. 78:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
11	Mesiano G, Todorovic M, Gammaitoni L, et al: Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther. 12:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
12	Helms MW, Prescher JA, Cao YA, et al: IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother. 59:1325–1334. 2010. View Article : Google Scholar : PubMed/NCBI
13	Chan JK, Hamilton CA, Cheung MK, et al: Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 12:1859–1867. 2006. View Article : Google Scholar
14	Frumento G, Zheng Y, Aubert G, et al: Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant. 13:45–55. 2013. View Article : Google Scholar
15	Introna M, Pievani A, Borleri G, et al: Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant. 16:1603–1607. 2010. View Article : Google Scholar : PubMed/NCBI
16	Li J, Wang QH, Wu HM, et al: A survey of neonatal births in maternity departments in urban China in 2005. Zhongguo Dang Dai Er Ke Za Zhi. 14:7–10. 2012.(In Chinese).
17	Krzewski K, Gil-Krzewska A, Nguyen V, et al: LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood. 121:4672–4683. 2013. View Article : Google Scholar : PubMed/NCBI
18	Jiang J, Wu C and Lu B: Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 11:832013. View Article : Google Scholar : PubMed/NCBI
19	Durrieu L, Gregoire-Gauthier J, Dieng MM, et al: Human interferon-α increases the cytotoxic effect of CD56⁺ cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy. 14:1245–1257. 2012.
20	Li R, Wang C, Liu L, et al: Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother. 61:2125–2133. 2012. View Article : Google Scholar : PubMed/NCBI
21	Yang L, Ren B, Li H, et al: Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 62:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
22	D’Alessio F, Mirabelli P, Gorrese M, et al: Polychromatic flow cytometry analysis of CD34⁺ hematopoietic stem cells in cryopreserved early preterm human cord blood samples. Cytometry A. 79:14–24. 2011.
23	Kornacker M, Moldenhauer G, Herbst M, et al: Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer. 119:1377–1382. 2006.PubMed/NCBI
24	Zanon C, Stocchero M, Albiero E, et al: Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells. Cytometry B Clin Cytom. 86:257–262. 2014. View Article : Google Scholar : PubMed/NCBI
25	Niu Q, Wang W, Li Y, et al: Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol. 11:449–456. 2011. View Article : Google Scholar : PubMed/NCBI
26	van Lier RA, Borst J, Vroom TM, et al: Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol. 139:1589–1596. 1987.PubMed/NCBI
27	Taraban VY, Rowley TF, Kerr JP, et al: CD27 costimulation contributes substantially to the expansion of functional memory CD8⁺ T cells after peptide immunization. Eur J Immunol. 43:3314–3323. 2013. View Article : Google Scholar : PubMed/NCBI
28	Pufnock JS, Cigal M, Rolczynski LS, et al: Priming CD8⁺ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8⁺ T cells retaining CD28. Blood. 117:6542–6551. 2011.
29	Prosser ME, Brown CE, Shami AF, et al: Tumor PD-L1 co-stimulates primary human CD8⁺ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 51:263–272. 2012. View Article : Google Scholar : PubMed/NCBI
30	Saga K, Tamai K, Yamazaki T, et al: Systemic administration of a novel immune-stimulatory pseudovirion suppresses lung metastatic melanoma by regionally enhancing IFN-γ production. Clin Cancer Res. 19:668–679. 2013.PubMed/NCBI
31	Wang Y, Bo J, Dai HR, et al: CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp Hematol. 41:241–252. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wang YF, Kunda PE, Lin JW, et al: Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol Rep. 29:1841–1850. 2013.
33	Introna M, Franceschetti M, Ciocca A, et al: Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 38:621–627. 2006. View Article : Google Scholar
34	Kim TD, Lee SU, Yun S, et al: Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. Blood. 118:5476–5486. 2011. View Article : Google Scholar : PubMed/NCBI
35	Alter G, Malenfant JM and Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 294:15–22. 2004. View Article : Google Scholar : PubMed/NCBI